Daunorubicin Injection

• Type: Chemotherapy medication

• Drug Class: Anthracycline antibiotic (antineoplastic agent)

• Form: Sterile solution or powder for reconstitution, given intravenously (IV)

How It Works

• Daunorubicin works by intercalating into DNA (slipping between DNA strands) and inhibiting topoisomerase II, an enzyme that helps unwind DNA during replication.

• This blocks DNA and RNA synthesis, preventing cancer cells from dividing.

• It also produces free radicals, which damage cancer cell DNA and cell membranes, leading to cell death.

Common Uses

Daunorubicin is mainly used to treat blood cancers:

• Acute Myeloid Leukemia (AML) – as part of induction chemotherapy

• Acute Lymphoblastic Leukemia (ALL) – in some treatment regimens

• Other leukemias – in selected cases

Advantages

• Highly effective at inducing remission in AML and ALL

• Often combined with cytarabine (the “7+3 regimen”) for better results

• Rapidly kills rapidly dividing leukemia cells

Possible Side Effects

Daunorubicin has some specific side effects that require monitoring:

Common

• Bone marrow suppression (low blood counts, risk of infection, anemia, bleeding)

• Hair loss (alopecia)

• Nausea, vomiting, mouth sores

• Red coloration of urine for 1–2 days after dose (harmless but expected)

Serious

• Heart toxicity (cardiotoxicity) – risk of heart damage increases with cumulative dose

• Tissue damage if drug leaks outside vein (extravasation) – can cause severe local injury

• Liver function abnormalities

• Rare: secondary leukemia with prolonged use

Precautions

• Heart function (e.g., echocardiogram) is checked before and sometimes during treatment

• Maximum lifetime cumulative dose must not be exceeded to reduce heart failure risk

• Administered only through a properly placed IV line by trained professionals

• Blood counts and liver function monitored closely